Plasma Sphingolipids in Relation to Glycemia and Glucose Tolerance in People Without Diabetes
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf378 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Peace Asuzu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Hauptthemen laut MEDLINE: Sphingolipids, Blood Glucose, Glucose Intolerance, Prediabetic State. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institutes of Diabetes Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Sphingolipids have been linked to the pathogenesis of type 2 diabetes.
Objective
To examine the association of plasma sphingolipids with glycemic measures in adults without diabetes.
Methods
Plasma sphingolipid species (ceramides, monohexosyl ceramides, lactosyl ceramides, sphingomyelins, and sphingosines) were assayed using liquid chromatography tandem mass spectrometry in baseline specimens obtained from participants in the Pathobiology of Prediabetes in a Biracial Cohort study (n = 240) and the Diabetes Prevention Program (n = 280). Based on oral glucose tolerance tests, we identified participants with (1) normal fasting plasma glucose (NFG) (<100 mg/dL) and normal glucose tolerance (NGT) [2-hour plasma glucose (2hPG) < 140 mg/dL]; (2) impaired fasting glucose (IFG; 100-125 mg/dL) with normal 2hPG; (3) impaired glucose tolerance (IGT) (2hPG 140-199 mg/dL with NFG); and (4) IFG and IGT.
Results
The participants (63% female; 48% Black, 52% White) had a mean age of 45.5 ± 9.84 years, body mass index (BMI) 32.4 ± 7.24 kg/m2, fasting plasma glucose (FPG) 99.8 ± 10.5 mg/dL, and 2hPG 145 ± 29.4 mg/dL. FPG and 2hPG levels correlated positively with ceramides, sphingomyelins, and sphingosine and inversely with monohexosyl ceramides, lactosyl ceramides, and sphingosine-1 phosphate levels, adjusted for age, sex, race, and BMI. Plasma ceramides, sphingomyelins, and sphingosine increased progressively across participants with NFG-NGT, isolated IGT, and IFG-IGT, whereas the opposite was seen for monohexosyl ceramides, lactosyl ceramides, and sphingosine-1 phosphate levels (ANOVA P < .0001).
Conclusion
Circulating levels of major sphingolipid species are significantly associated with glycemia and glucose tolerance, indicating a possible link between sphingolipid metabolism and glucoregulation in people without diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
ORCID-Profile: Nawajes Mandal, Samuel Dagogo-Jack
Förderung
- NIDDK NIH HHS
- National Institutes of Diabetes Digestive and Kidney Diseases
Zitieren
APA
Asuzu, P., Aliye, N., Stentz, F., Wan, J., Mandal, N., & Dagogo-Jack, S. (2026). Plasma Sphingolipids in Relation to Glycemia and Glucose Tolerance in People Without Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf378
Vancouver
Asuzu P, Aliye N, Stentz F, Wan J, Mandal N, Dagogo-Jack S. Plasma Sphingolipids in Relation to Glycemia and Glucose Tolerance in People Without Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf378
BibTeX
@article{Asuzu2026,
author = {Asuzu, Peace and Aliye, Naser and Stentz, Frankie and Wan, Jim and Mandal, Nawajes and Dagogo-Jack, Samuel},
title = {Plasma Sphingolipids in Relation to Glycemia and Glucose Tolerance in People Without Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf378}
}
EUVIMED